1-8 of 8
Oona Delpuech
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Vikki Flemington, Emma J. Davies, David Robinson, Linda C. Sandin, Oona Delpuech, Pei Zhang, Lyndsey Hanson, Paul Farrington, Sigourney Bell, Katarzyna Falenta, Francis D. Gibbons, Nicola Lindsay, Aaron Smith, Joanne Wilson, Karen Roberts, Michael Tonge, Philip Hopcroft, Sophie E. Willis, Martine P. Roudier, Claire Rooney, Elizabeth A. Coker, Patricia Jaaks, Mathew J. Garnett, Stephen E. Fawell, Clifford D. Jones, Richard A. Ward, Iain Simpson, Sabina C. Cosulich, J. Elizabeth Pease, Paul D. Smith
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (2): 238–249.
https://doi.org/10.1158/1535-7163.MCT-20-0002
Published: 05 February 2021
View articletitled, AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Open the PDF for AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib in another window
Includes: Supplementary data
Journal Articles

Abstract A117: The epigenome and gene expression landscape of osimeritib drug tolerant persister cells

Steven W Criscione, Matthew Martin, Yi Yao, Aleksandra Markovets, Jingwen Zhang, Sladjana Gagrica, Oona Delpuech, Zhongwu Lai, Paul Smith, Jonathan Dry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A117.
https://doi.org/10.1158/1535-7163.TARG-19-A117
Published: 01 December 2019
View articletitled, Abstract A117: The epigenome and gene expression landscape of osimeritib drug tolerant persister cells
Journal Articles

Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors

James T. Lynch, Urszula M. Polanska, Ursula Hancox, Oona Delpuech, Juliana Maynard, Catherine Trigwell, Catherine Eberlein, Carol Lenaghan, Radoslaw Polanski, Alvaro Avivar-Valderas, Marie Cumberbatch, Teresa Klinowska, Susan E. Critchlow, Francisco Cruzalegui, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (11): 2309–2319.
https://doi.org/10.1158/1535-7163.MCT-18-0183
Published: 02 November 2018
View articletitled, Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors
Open the PDF for Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors in another window
Includes: Supplementary data
Journal Articles

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

Chrysiis Michaloglou, Claire Crafter, Rasmus Siersbaek, Oona Delpuech, Jon O. Curwen, Larissa S. Carnevalli, Anna D. Staniszewska, Urszula M. Polanska, Azadeh Cheraghchi-Bashi, Mandy Lawson, Igor Chernukhin, Robert McEwen, Jason S. Carroll, Sabina C. Cosulich
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (5): 908–920.
https://doi.org/10.1158/1535-7163.MCT-17-0537
Published: 30 April 2018
View articletitled, Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
Open the PDF for Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547

Oona Delpuech, Claire Rooney, Lorraine Mooney, Dawn Baker, Robert Shaw, Michael Dymond, Dennis Wang, Pei Zhang, Sarah Cross, Margaret Veldman-Jones, Joanne Wilson, Barry R. Davies, Jonathan R. Dry, Elaine Kilgour, Paul D. Smith
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (11): 2802–2813.
https://doi.org/10.1158/1535-7163.MCT-16-0297
Published: 01 November 2016
View articletitled, Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
Open the PDF for Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547 in another window
Includes: Supplementary data
Journal Articles

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Kevin Hudson, Urs J. Hancox, Cath Trigwell, Robert McEwen, Urszula M. Polanska, Myria Nikolaou, Pablo Morentin Gutierrez, Alvaro Avivar-Valderas, Oona Delpuech, Phillippa Dudley, Lyndsey Hanson, Rebecca Ellston, Alys Jones, Marie Cumberbatch, Sabina C. Cosulich, Lara Ward, Francisco Cruzalegui, Stephen Green
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (5): 877–889.
https://doi.org/10.1158/1535-7163.MCT-15-0687
Published: 05 May 2016
View articletitled, Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Open the PDF for Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers in another window
Includes: Supplementary data
Journal Articles

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D'Cruz, James W.T. Yates, Michael Grondine, Zoe Howard, Barry R. Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula M. Polanska, Robert McEwen, Oona Delpuech, Stephen Green, Sabina C. Cosulich
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (11): 2508–2518.
https://doi.org/10.1158/1535-7163.MCT-15-0365
Published: 03 November 2015
View articletitled, AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Open the PDF for AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules in another window
Includes: Supplementary data
Journal Articles

Abstract C144: MAPK1 mutation E322K modulates ERK pathway output and feedback.

Nin Guan, Oona Delpuech, Danielle Greenawalt, Kelly Jacques, Farzin Gharahdaghi, Michael Zinda, Paul J. Smith, Sylvie M. Guichard
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C144.
https://doi.org/10.1158/1535-7163.TARG-13-C144
Published: 01 November 2013
View articletitled, Abstract C144: MAPK1 mutation E322K modulates ERK pathway output and feedback.